At the IGTP TODAY

News

- Research

A new tool that makes it possible to adapt treatment for patients with cardiogenic shock has been discovered

Cardiogenic shock is a possible complication of serious heart attack involving an associated mortality rate of approximately 50% of all cases. The combination of this new tool with existing methods renders precise and patient-specific decision-making possible. The research is being led by Dr. Antoni Bayés at Germans Trias and the Proteomics Unit of the CRG and UPF, under Dr. Eduard Sabidó

Manremyc opens a funding round of 250,000 euros through the Capital Cell platform

Manremyc, a spin-off of the IGTP specialised in the development of a probiotic against tuberculosis, has opened a funding round through Capital Cell, the first on-line investment platform in Europe specialized in biomedicine. The objective of the campaign is to reach 250,000 euros, with a minimum investment requirement per person of only 600 euros. Up to now, the company has secured 35% of the investment, which includes participation from the Reig family, main shareholders in the pharmaceutical company Reig Jofre.

- Research

The IGTP participates in the debates of the 11th Research Workshop of the ICS: childhood obesity and rare diseases

Experts in paediatric research agree on the need to anticipate and act on obesity from childhood. The importance of early interventions to prevent obesity and excess weight and research into rare diseases have been the main topics of the 11th Research Workshop of the Catalan Institute of Health (ICS), which took place at the Seminari de Tarragona (Centre Tarraconense).

- Innovation, Research

Aniling is among the projects selected for this year’s CRAASH Barcelona Programme

Ten international projects have been selected for the second edition of CRAASH Barcelona and Aniling is one of them.  CRAASH is the business acceleration programme organized by Biocat and CIMIT (Boston). Aniling is a spin-off company of the IGTP, which has developed a method for analysing the genome and epigenome of a patient simultaneously, an advance in personalized medicine for both research and clinical settings.

- Research

Seeking a consensus for Extracellular Vesicle Isolation

This year the Innovation in Vesicles and Cells for Application in Therapy (IVECAT) has published a protocol for Size-Exclusion Chromatography for separating extracellular vesicles from different biological fluids and a review of the current techniques available.

- Campus Can Ruti, Research

New financing from the Catalan NF2 Patients Association for Research into personalized medicine for Neurofibromatosis Type 2

Can Ruti has been awarded a research project by the Spanish Federation for Rare Diseases (FEDER) Foundation in their fourth call for research projects.  The winning project, led by Dr Ignacio Blanco and Dr Elisabeth Castellanos, from the Germans Trias I Pujol Hospital and Institute respectively, is one of five financed by the foundation this year. The research will focus personalized attention for Neurofibromatosis type 2 (NF2) patients to optimize evaluation of their quality of life and refine their classification during diagnosis.

- Research

Elisa Martró awarded a project for Micro-elimination of Hepatitis C by GILEAD

Elisa Martró, leader of the Clinical Virology and New Diagnostic Approaches Research Group at the Microbiology Service of the Germans Trias i Pujol Hospital, has been awarded with one of the five projects granted in the First Edition of the Gilead projects for Micro-elimination of Hepatitis C in Spain and evaluated by the Spanish Liver Research Association (AEEH).